FDA asks Sarepta to stop shipping gene therapy
Digest more
Massachusetts-based Sarepta Therapeutics, facing scrutiny from regulators, is reducing its global workforce by 36% in an effort to cut annual operating costs by hundreds of millions of dollars.
Groundbreaking new research shows that it is possible to use gene therapy to restore hearing in both children and adults.
Sarepta Therapeutics will cut 500 jobs and add a serious warning on the label of its muscle-disorder gene therapy Elevidys, the drugmaker said on Wednesday, following the recent deaths of two patients who were on the medicine.
A team of Chinese medical experts say they can produce anti-cancer cells directly inside the human body using gene therapy tools.
Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy appeared at risk. Sarepta has reported three patient deaths related to its gene therapies.
Explore more
Our Bureau, Mumbai Friday, July 18, 2025, 17:45 Hrs [IST]
The Centers for Medicare and Medicaid Services (CMS) has selected 35 participants for its new, voluntary Cell and Gene Therapy Access Model. | As expected, there will be 35 voluntary participants in the CMS' new Cell and Gene Therapy Access Model.